Semaglutide Options Online: What Patients Should Know

Ozempic vs Wegovy vs Compounded Semaglutide: The Difference That Matters

Ozempic, Wegovy, and compounded semaglutide all contain semaglutide — but they are not interchangeable. Ozempic (0.5mg, 1mg, 2mg weekly) is FDA-approved for type 2 diabetes and to reduce cardiovascular risk in adults with type 2 diabetes and established cardiovascular disease. Wegovy (2.4mg weekly) is FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition, and for cardiovascular risk reduction in those with established disease.

Compounded semaglutide is not FDA-approved for any indication and is not a generic version of either branded product. Patients who see the phrase 'generic Ozempic' on a website should treat it as a serious red flag — FDA explicitly warns that this language is misleading.

The SELECT trial (NEJM 2023) found a 20% reduction in major adverse cardiovascular events with semaglutide in adults with overweight or obesity and established cardiovascular disease. The STEP 1 trial (NEJM 2021) found 14.9% mean weight loss at 68 weeks. Both studied FDA-approved formulations.

Why Many Patients Search Ozempic Instead of Wegovy

Ozempic became widely known through media coverage and celebrity discussion around 2022-2023. Many patients associate the name Ozempic with weight loss even though Wegovy is the FDA-approved weight management product. Providers who prescribe Ozempic off-label for weight loss are making an individual clinical decision — not following the FDA-approved indication. Ozari Health prescribes semaglutide-based treatment within appropriate clinical and regulatory parameters.

Comparison Table

Red Flags — Avoid These Providers

Frequently Asked Questions

Can Ozempic be prescribed online?

Yes — online prescribing can be appropriate when a licensed provider reviews medical history and determines Ozempic is clinically appropriate for the patient's specific diagnosis.

Is Ozempic approved for weight loss?

Ozempic is FDA-approved for type 2 diabetes and cardiovascular risk reduction in adults with type 2 diabetes. Wegovy is the semaglutide brand approved for chronic weight management.

Is compounded semaglutide the same as Ozempic?

No. Compounded semaglutide is not FDA-approved and is not generic Ozempic. Any seller using that language is providing misleading information — the FDA has specifically warned against it.

What should I do if I want semaglutide for weight loss but don't have diabetes?

Wegovy is the FDA-approved branded semaglutide product for chronic weight management and doesn't require a diabetes diagnosis. Compounded semaglutide through a licensed telehealth provider is another option for eligible cash-pay patients.

Does Ozari offer semaglutide?

Yes. Ozari offers online provider review for semaglutide-based treatment options. Compounded semaglutide starts at $86/month for eligible patients. Ozari does not position its offering as 'Ozempic.'

What happens if a provider prescribes Ozempic for weight loss?

Prescribing Ozempic for weight loss is an off-label use. It may be appropriate in some clinical contexts based on provider judgment, but Wegovy (semaglutide 2.4mg) is the FDA-approved weight management indication.

---

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality. Clinical trial results for FDA-approved products should not be extrapolated as guaranteed outcomes for compounded medications. Individual results vary. Always consult a licensed healthcare provider before starting any prescription medication. Ozari Health is a telehealth platform that connects patients with licensed, independent healthcare providers.

---

Sources

FDA label — Ozempic semaglutide injection: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79

FDA — Wegovy approval and cardiovascular risk indication: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or

STEP 1 semaglutide trial (PubMed): https://pubmed.ncbi.nlm.nih.gov/33567185/

SELECT cardiovascular outcomes trial (NEJM): https://pubmed.ncbi.nlm.nih.gov/37832195/

FDA — Concerns with unapproved GLP-1 drugs: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

Ozari Health semaglutide pricing: https://www.ozarihealth.com/treatments/semaglutide